Open AccessEPITHET
Author(s) -
Yoshinari Nagakane,
Hanne Christensen,
Caspar Brekenfeld,
Henry Ma,
Leonid Churilov,
Mark Parsons,
Christopher Levi,
Kenneth Butcher,
André Peeters,
P. Alan Barber,
Christopher F. Bladin,
Deidre Anne De Silva,
John Fink,
Thomas Kimber,
David Schultz,
Keith W. Muir,
Brian M. Tress,
Patricia Desmond,
Stephen M. Davis,
Geoffrey A. Donnan
Publication year - 2010
Publication title -
stroke
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.397
H-Index - 319
eISSN - 1524-4628
pISSN - 0039-2499
DOI - 10.1161/strokeaha.110.580464
Subject(s) - medicine , placebo , nuclear medicine , stroke (engine) , perfusion , randomized controlled trial , thrombolysis , penumbra , surgery , radiology , ischemia , myocardial infarction , pathology , mechanical engineering , alternative medicine , engineering
he Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET) was a prospective, randomized, double-blinded, placebo-controlled, phase II trial of alteplase between 3 and 6 hours after stroke onset. The primary outcome of infarct growth attenuation on MRI with alteplase in mismatch patients was negative when mismatch volumes were assessed volumetrically, without coregistration, which underestimates mismatch volumes. We hypothesized that assessing the extent of mismatch by coregistration of perfusion and diffusion MRI maps may more accurately allow the effects of alteplase vs placebo to be evaluated.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom